A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

This is a Phase I/II, dose-escalation and expansion study of NUC-7738 administered by intravenous infusion as a monotherapy and in combination with pembrolizumab. In Phase I, NUC-7738 monotherapy is evaluated across two administration schedules (weekly or fortnightly) in a dose-escalation design in patients with advanced solid tumours. The main objectives are to assess the safety and tolerability of NUC-7738, in addition to establishing the Maximum Tolerated Dose (MTD) and dose administration schedule of NUC-7738 for further exploration in the Phase II part of the study. In Phase II, the sel

Trial Details

NCT ID
NCT03829254
Phase
PHASE1 / PHASE2
Sponsor
NuCana plc
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • NUC-7738
  • Pembrolizumab
Locations (sample)
  • Cambridge, United Kingdom|52.2,0.11667
  • Edinburgh, United Kingdom|55.95206,-3.19648
  • Glasgow, United Kingdom|55.86515,-4.25763
  • London, United Kingdom|51.50853,-0.12574
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Provision of signed written informed consent.
  • Solid tumour cohorts only (Phase I and Phase II; excluding NUC-7738 + pembrolizumab cohort): Histologically confirmed diagnosis of an advanced soli…
  • NUC-7738 + pembrolizumab cohort only (Phase II): Histologically confirmed diagnosis of metastatic cutaneous melanoma with measurable disease as per…
  • Lymphoma cohort only (Phase II): Relapsed refractory lymphoma (high grade and low grade B-NHL, Hodgkin's Lymphoma and T-cell lymphomas), which is n…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →